Chronic exposure to rifaximin causes hepatic steatosis in pregnane X receptor-humanized mice

Toxicological Sciences

Volumn 129, Issue 2, 2012, Pages 456-468

  Cheng, Jie ^a   Krausz, Kristopher W ^a   Tanaka, Naoki ^a   Gonzalez, Frank J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Hepatotoxicity; Human pregnane X receptor; Rifaximin; Steatosis

Indexed keywords

ACYL COENZYME A DESATURASE; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ALANINE AMINOTRANSFERASE; ALPHA ACTININ 2; ASPARTATE AMINOTRANSFERASE; CD36 ANTIGEN; COLLAGEN TYPE 1; DIACYLGLYCEROL ACYLTRANSFERASE 1; FATTY ACID; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PREGNANE X RECEPTOR; RIFAXIMIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR BETA1; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG SAFETY; FATTY LIVER; GENE ACTIVATION; GENE EXPRESSION; INTESTINE EPITHELIUM CELL; JEJUNUM; LIPID TRANSPORT; LIVER; LIVER FUNCTION; LIVER HISTOLOGY; MALE; MOUSE; NONHUMAN; OXIDATION; SMALL INTESTINE; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; WESTERN BLOTTING; WILD TYPE;

ANIMALS; ANTI-INFECTIVE AGENTS; FATTY LIVER; HUMANS; LIPID METABOLISM; MICE; RECEPTORS, STEROID; RIFAMYCINS;

MUS;

EID: 84866606730     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfs211     Document Type: Article

References (45)

1. Brookheart, R. T., Michel, C. I., and Schaffer, J. E. (2009). As a matter of fat. Cell Metab. 10, 9-12.
2. Brunet, S., Thibault, L., Delvin, E., Yotov, W., Bendayan, M., and Levy, E. (1999). Dietary iron overload and induced lipid peroxidation are associated with impaired plasma lipid transport and hepatic sterol metabolism in rats. Hepatology 29, 1809-1817.
3. Cheng, J., Ma, X., and Gonzalez, F. J. (2011). Pregnane X receptor- and CYP3A4-humanized mouse models and their applications. Br. J. Pharmacol. 163, 461-468.
4. Cheng, J., Ma, X., Krausz, K. W., Idle, J. R., and Gonzalez, F. J. (2009). Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity. Drug Metab. Dispos. 37, 1611-1621.
5. Cheng, J., Shah, Y. M., and Gonzalez, F. J. (2012). Pregnane X receptor as a target for treatment of inflammatory bowel disorders. Trends Pharmacol. Sci. 33, 323-340.
6. Cheng, J., Shah, Y. M., Ma, X., Pang, X., Tanaka, T., Kodama, T., Krausz, K. W., and Gonzalez, F. J. (2010). Therapeutic role of rifaximin in inflammatory bowel disease: Clinical implication of human pregnane X receptor activation. J. Pharmacol. Exp. Ther. 335, 32-41.
7. Cianflone, K., Paglialunga, S., and Roy, C. (2008). Intestinally derived lipids: Metabolic regulation and consequences-An overview. Atheroscler. Suppl. 9, 63-68.
8. Corazza, G. R., Sorge, M., Strocchi, A., Benati, G., Di Sario, A., Treggiari, E. A., Brusco, G., and Gasbarrini, G. (1992). Non-absorbable antibiotics and small bowel bacterial overgrowth. Ital. J. Gastroenterol. 24(9 Suppl 2), 4-9.
9. Green, P. H., and Riley, J. W. (1981). Lipid absorption and intestinal lipoprotein formation. Aust. NZ J. Med. 11, 84-90.
10. Hardie, D. G., Ross, F. A., and Hawley, S. A. (2012). AMPK: A nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 13, 251-262.
11. Hoekstra, M., Lammers, B., Out, R., Li, Z., Van Eck, M., and Van Berkel, T. J. (2009). Activation of the nuclear receptor PXR decreases plasma LDL-cholesterol levels and induces hepatic steatosis in LDL receptor knockout mice. Mol. Pharm. 6, 182-189.
12. Huhulescu, S., Sagel, U., Fiedler, A., Pecavar, V., Blaschitz, M., Wewalka, G., Allerberger, F., and Indra, A. (2011). Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile. J. Med. Microbiol. 60(Pt 8), 1206-1212.
13. Kalambokis, G. N., and Tsianos, E. V. (2012). Rifaximin reduces endotoxemia and improves liver function and disease severity in patients with decompensated cirrhosis. Hepatology 55, 655-656.
14. Khan, K. J., Ullman, T. A., Ford, A. C., Abreu, M. T., Abadir, A., Marshall, J. K., Talley, N. J., and Moayyedi, P. (2011). Antibiotic therapy in inflammatory bowel disease: A systematic review and meta-analysis. Am. J. Gastroenterol. 106, 661-673.
15. Kisfali, P., Polgar, N., Safrany, E., Sumegi, K., Melegh, B. I., Bene, J., Weber, A., Hetyesy, K., and Melegh, B. (2010). Triglyceride level affecting shared susceptibility genes in metabolic syndrome and coronary artery disease. Curr. Med. Chem. 17, 3533-3541.
16. Levy, E., Menard, D., Delvin, E., Montoudis, A., Beaulieu, J. F., Mailhot, G., Dube, N., Sinnett, D., Seidman, E., and Bendayan, M. (2009). Localization, function and regulation of the two intestinal fatty acid-binding protein types. Histochem. Cell Biol. 132, 351-367.
17. Lorbek, G., Lewinska, M., and Rozman, D. (2012). Cytochrome P450s in the synthesis of cholesterol and bile acids-From mouse models to human diseases. FEBS J. 279, 1516-1533.
18. Ma, X., Shah, Y. M., Guo, G. L., Wang, T., Krausz, K. W., Idle, J. R., and Gonzalez, F. J. (2007). Rifaximin is a gut-specific human pregnane X receptor activator. J. Pharmacol. Exp. Ther. 322, 391-398.
19. Maclayton, D. O., and Eaton-Maxwell, A. (2009). Rifaximin for treatment of hepatic encephalopathy. Ann. Pharmacother. 43, 77-84.
20. Martin, C., Chevrot, M., Poirier, H., Passilly-Degrace, P., Niot, I., and Besnard, P. (2011). CD36 as a lipid sensor. Physiol. Behav. 105, 36-42.
21. Mellitzer, G., and Gradwohl, G. (2011). Enteroendocrine cells and lipid absorption. Curr. Opin. Lipidol. 22, 171-175.
22. Minguez, B., and Lachenmayer, A. (2011). Diagnostic and prognostic molecular markers in hepatocellular carcinoma. Dis. Markers 31, 181-190.
23. Moreau, A., Teruel, C., Beylot, M., Albalea, V., Tamasi, V., Umbdenstock, T., Parmentier, Y., Sa-Cunha, A., Suc, B., Fabre, J. M., et al. (2009). A novel pregnane X receptor and S14-mediated lipogenic pathway in human hepatocyte. Hepatology 49, 2068-2079.
24. Moya, M., Gomez-Lechon, M. J., Castell, J. V., and Jover, R. (2010). Enhanced steatosis by nuclear receptor ligands: A study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile. Chem. Biol. Interact. 184, 376-387.
25. Nelson, R. (2007). Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst. Rev. 3, CD004610.
26. Ojetti, V., Lauritano, E. C., Barbaro, F., Migneco, A., Ainora, M. E., Fontana, L., Gabrielli, M., and Gasbarrini, A. (2009). Rifaximin pharmacology and clinical implications. Expert Opin. Drug Metab. Toxicol. 5, 675-682.
27. Ozer, J., Ratner, M., Shaw, M., Bailey, W., and Schomaker, S. (2008). The current state of serum biomarkers of hepatotoxicity. Toxicology 245, 194-205.
28. Peach, M., Marsh, N., and Macphee, D. J. (2012). Protein solubilization: Attend to the choice of lysis buffer. Methods Mol. Biol. 869, 37-47.
29. Pimentel, M. (2009). Review of rifaximin as treatment for SIBO and IBS. Expert Opin. Investig. Drugs 18, 349-358.
30. Ponugoti, B., Fang, S., and Kemper, J. K. (2007). Functional interaction of hepatic nuclear factor-4 and peroxisome proliferator-activated receptor-gamma coactivator 1alpha in CYP7A1 regulation is inhibited by a key lipogenic activator, sterol regulatory element-binding protein-1c. Mol. Endocrinol. 21, 2698-2712.
31. Roth, A., Looser, R., Kaufmann, M., Blattler, S. M., Rencurel, F., Huang, W., Moore, D. D., and Meyer, U. A. (2008). Regulatory cross-talk between drug metabolism and lipid homeostasis: Constitutive androstane receptor and pregnane X receptor increase Insig-1 expression. Mol. Pharmacol. 73, 1282-1289.
32. Sandoval, J. C., Nakagawa-Toyama, Y., Masuda, D., Tochino, Y., Nakaoka, H., Kawase, R., Yuasa-Kawase, M., Nakatani, K., Inagaki, M., Tsubakio-Yamamoto, K., Ohama, T., Matsuyama, A., et al. (2010). Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia. J. Atheroscler. Thromb. 17, 914-924.
33. Schote, A. B., Turner, J. D., Schiltz, J., and Muller, C. P. (2007). Nuclear receptors in human immune cells: expression and correlations. Mol. Immunol. 44, 1436-1445.
34. Smelt, A. H. (2010). Triglycerides and gallstone formation. Clin. Chim. Acta 411, 1625-1631.
35. Sookoian, S., Castano, G. O., Burgueno, A. L., Gianotti, T. F., Rosselli, M. S., and Pirola, C. J. (2010). The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. Pharmacogenet. Genomics 20, 1-8.
36. Sui, Y., Xu, J., Rios-Pilier, J., and Zhou, C. (2011). Deficiency of PXR decreases atherosclerosis in ApoE-deficient mice. J. Lipid Res. 52, 1652-1659.
37. Tanaka, N., Matsubara, T., Krausz, K. W., Patterson, A. D., and Gonzalez, F. J. (2012). Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology 56, 118-129.
38. Taylor, D. N., Bourgeois, A. L., Ericsson, C. D., Steffen, R., Jiang, Z. D., Halpern, J., Haake, R., and Dupont, H. L. (2006). A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am. J. Trop. Med. Hyg. 74, 1060-1066.
39. Triantafillidis, J. K., Merikas, E., and Georgopoulos, F. (2011). Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des. Devel. Ther. 5, 185-210.
40. Valentin, T., Leitner, E., Rohn, A., Zollner-Schwetz, I., Hoenigl, M., Salzer, H. J., and Krause, R. (2011). Rifaximin intake leads to emergence of rifampin-resistant staphylococci. J. Infect. 62, 34-38.
41. Viollet, B., Guigas, B., Leclerc, J., Hebrard, S., Lantier, L., Mounier, R., Andreelli, F., and Foretz, M. (2009). AMP-activated protein kinase in the regulation of hepatic energy metabolism: From physiology to therapeutic perspectives. Acta Physiol. (Oxf.) 196, 81-98.
42. Yang, Z. X., Shen, W., and Sun, H. (2010). Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease. Hepatol. Int. 4, 741-748.
43. Zhang, B., Xie, W., and Krasowski, M. D. (2008). PXR: A xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics 9, 1695-1709.
44. Zhou, J., Febbraio, M., Wada, T., Zhai, Y., Kuruba, R., He, J., Lee, J. H., Khadem, S., Ren, S., Li, S., et al. (2008). Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology 134, 556-567.
45. Zhou, J., and Xie, W. (2006). A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway. J. Biol. Chem. 281, 15013-15020.